KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCQB:PVCT) (http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, has received U.S. Patent No. 8,557,298 from the United States Patent and Trademark Office (USPTO), a continuation-in-part of U.S. Patent No. 7,648,695. Both patents provide coverage for new chemotherapeutical medicaments and medical uses for the treatment of cancer.
Help employers find you! Check out all the jobs and post your resume.